MRCM
MACK

M&R Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

M&R Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-64
Closed -$3K – 596
2016
Q3 		$3K Hold
64
– – ﹤0.01% 501
2016
Q2 		$2K Buy
+64
New +$3.49K ﹤0.01% 502

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

M&R Capital Management's MACK Position: Q4 2016 in Review

M&R Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 64 shares — an estimated $3K sold.

M&R Capital Management first reported a position in MACK in Q2 2016 and held it in 2 quarters. The position peaked at $3K in Q3 2016. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

  • M&R Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • M&R Capital Management sold 64 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $3K.
  • M&R Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
  • M&R Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $3K in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on M&R Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.